Pyrexar Medical Acquires Hyperthermia Assets of BSD Medical
-- Promising Cancer Treatment Technology Now Under New Leadership
SALT LAKE CITY, April 2, 2015 /PRNewswire/ -- Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon (NASDAQ:PRSN), formerly BSD Medical (NASDAQ:BSDM). This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.
Photo - http://photos.prnewswire.com/prnh/20150402/196321
Medical device industry veteran Mark Falkowski has been named Chief Executive Officer bringing to Pyrexar more than 30 years of successful executive leadership experience with prominent medical companies like GE Healthcare, Imatron, Carestream and OEC/Diasonics.
Mr. Falkowski recruited seasoned capital equipment executives, A. Robert Depalma, Brian Chard, Rex Harmon and Drew Wilkens. Also joining, former Perseon employees Paul Turner, Ray Lauritzen, Richard Faux, Dennis Bradley and a group of highly trained system design, production and customer support team members directly associated with the hyperthermia product line. The new group's goal is to build a sales and customer focused company.
Mr. Falkowski said: "New minimally invasive treatment technologies are vital to winning the fight against cancer and I look forward to taking an active part in bringing this important cancer fighting medical technology to market."
Pyrexar will be presenting and exhibiting at the upcoming Society for Thermal Medicine Annual Meeting in Orlando, FL (April 14-17, 2015).
ABOUT PYREXAR MEDICAL:
With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues.
Multi-center clinical trials in the US, Europe and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high risk soft tissue sarcoma, melanoma and other malignancies.
Pyrexar Medical is based in Salt Lake City, UT, USA. For more information please visit our web page at: pyrexar.com
Pyrexar Medical Media Contact:
Drew Wilkens
VP of Digital Marketing
+1-844-797-3927
drew.wilkens@pyrexar.com
Share this article